Wai Chun Bio-Technology (660) H1 2026 earnings summary

Executive summary

• Revenue for the six months ended 31 December 2025 rose 118.7% year-over-year to HK$352.2 million, driven by increased market demand and consumption.

• Gross profit increased to HK$35.7 million, but gross margin declined to 10.1% from 13.1% due to higher costs.

• Loss attributable to owners narrowed to HK$5.9 million from HK$13.7 million year-over-year, mainly due to higher revenue and lower finance costs.

• No interim dividend was declared for the period.

Financial highlights

• Administrative expenses rose 22.8% to HK$14.9 million, mainly from higher staff costs.

• Selling expenses surged 181.9% to HK$15.3 million, reflecting the revenue increase.

• Finance costs dropped 51.4% to HK$5.0 million due to maturity and alteration of convertible bonds.

• Net current liabilities improved to HK$61.2 million from HK$170.5 million as of 30 June 2025.

• Cash and cash equivalents stood at HK$5.6 million at period end.

Outlook and guidance

• Plans to pursue strategic acquisitions in the PRC to strengthen revenue and profit fundamentals.

• Management is negotiating with potential investors and implementing cost controls to improve working capital and cash flows.

• Actively identifying projects with growth potential for acquisitions or investments.